Literature DB >> 33362485

Neural Mechanisms Underlying the Rewarding and Therapeutic Effects of Ketamine as a Treatment for Alcohol Use Disorder.

Caroline E Strong1, Mohamed Kabbaj1.   

Abstract

Alcohol use disorder (AUD) is the most prevalent substance use disorder and causes a significant global burden. Relapse rates remain incredibly high after decades of attempting to develop novel treatment options that have failed to produce increased rates of sobriety. Ketamine has emerged as a potential treatment for AUD following its success as a therapeutic agent for depression, demonstrated by several preclinical studies showing that acute administration reduced alcohol intake in rodents. As such, ketamine's therapeutic effects for AUD are now being investigated in clinical trials with the hope of it being efficacious in prolonging sobriety from alcohol in humans (ClinicalTrials.gov, Identifier: NCT01558063). Importantly, ketamine's antidepressant effects only last for about 1-week and because AUD is a lifelong disorder, repeated treatment regimens would be necessary to maintain sobriety. This raises questions regarding its safety for AUD treatment since ketamine itself has the potential for addiction. Therefore, this review aims to summarize the neuroadaptations related to alcohol's addictive properties as well as ketamine's therapeutic and addictive properties. To do this, the focus will be on reward-related brain regions such as the nucleus accumbens (NAc), dorsal striatum, prefrontal cortex (PFC), hippocampus, and ventral tegmental area (VTA) to understand how acute vs. chronic exposure will alter reward signaling over time. Additionally, evidence from these studies will be summarized in both male and female subjects. Accordingly, this review aims to address the safety of repeated ketamine infusions for the treatment of AUD. Although more work about the safety of ketamine to treat AUD is warranted, we hope this review sheds light on some answers about the safety of repeated ketamine infusions.
Copyright © 2020 Strong and Kabbaj.

Entities:  

Keywords:  addiction; alcohol use disorder (AUD); depression; ketamine; mechanisms

Year:  2020        PMID: 33362485      PMCID: PMC7759199          DOI: 10.3389/fnbeh.2020.593860

Source DB:  PubMed          Journal:  Front Behav Neurosci        ISSN: 1662-5153            Impact factor:   3.558


  142 in total

1.  Increasing doses of ketamine curtail antidepressant responses and suppress associated synaptic signaling pathways.

Authors:  Ji-Woon Kim; Lisa M Monteggia
Journal:  Behav Brain Res       Date:  2019-11-21       Impact factor: 3.332

2.  FACS-array profiling of striatal projection neuron subtypes in juvenile and adult mouse brains.

Authors:  Mary Kay Lobo; Stanislav L Karsten; Michelle Gray; Daniel H Geschwind; X William Yang
Journal:  Nat Neurosci       Date:  2006-02-19       Impact factor: 24.884

Review 3.  The hippocampal-VTA loop: controlling the entry of information into long-term memory.

Authors:  John E Lisman; Anthony A Grace
Journal:  Neuron       Date:  2005-06-02       Impact factor: 17.173

4.  Altered prefrontal dopaminergic function in chronic recreational ketamine users.

Authors:  Rajesh Narendran; W Gordon Frankle; Richard Keefe; Roberto Gil; Diana Martinez; Mark Slifstein; Lawrence S Kegeles; Peter S Talbot; Yiyun Huang; Dah-Ren Hwang; Leyla Khenissi; Thomas B Cooper; Marc Laruelle; Anissa Abi-Dargham
Journal:  Am J Psychiatry       Date:  2005-12       Impact factor: 18.112

5.  Effects of the non-competitive NMDA receptor antagonist ketamine on morphine-induced place preference in mice.

Authors:  T Suzuki; H Kato; T Aoki; M Tsuda; M Narita; M Misawa
Journal:  Life Sci       Date:  2000-06-16       Impact factor: 5.037

6.  D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons.

Authors:  C R Gerfen; T M Engber; L C Mahan; Z Susel; T N Chase; F J Monsma; D R Sibley
Journal:  Science       Date:  1990-12-07       Impact factor: 47.728

7.  The First Alcohol Drink Triggers mTORC1-Dependent Synaptic Plasticity in Nucleus Accumbens Dopamine D1 Receptor Neurons.

Authors:  Jacob T Beckley; Sophie Laguesse; Khanhky Phamluong; Nadege Morisot; Scott A Wegner; Dorit Ron
Journal:  J Neurosci       Date:  2016-01-20       Impact factor: 6.167

Review 8.  Efficacy and safety of sodium oxybate in alcohol-dependent patients with a very high drinking risk level.

Authors:  Wim van den Brink; Giovanni Addolorato; Henri-Jean Aubin; Amine Benyamina; Fabio Caputo; Maurice Dematteis; Antoni Gual; Otto-Michael Lesch; Karl Mann; Icro Maremmani; David Nutt; François Paille; Pascal Perney; Jürgen Rehm; Michel Reynaud; Nicolas Simon; Bo Söderpalm; Wolfgang H Sommer; Henriette Walter; Rainer Spanagel
Journal:  Addict Biol       Date:  2018-07       Impact factor: 4.280

9.  Ketamine Differentially Attenuates Alcohol Intake in Male Versus Female Alcohol Preferring (P) Rats.

Authors:  Amir H Rezvani; Edward D Levin; Marty Cauley; Bruk Getachew; Yousef Tizabi
Journal:  J Drug Alcohol Res       Date:  2017-07-28

10.  Binge-Like Alcohol Exposure During Adolescence Disrupts Dopaminergic Neurotransmission in the Adult Prelimbic Cortex.

Authors:  Heather Trantham-Davidson; Samuel W Centanni; S Corrin Garr; Natasha N New; Patrick J Mulholland; Justin T Gass; Elizabeth J Glover; Stan B Floresco; Fulton T Crews; Harish R Krishnan; Subhash C Pandey; L Judson Chandler
Journal:  Neuropsychopharmacology       Date:  2016-09-13       Impact factor: 7.853

View more
  3 in total

Review 1.  Helpful or Harmful? The Therapeutic Potential of Medications with Varying Degrees of Abuse Liability in the Treatment of Substance Use Disorders.

Authors:  Bradford Martins; Will Rutland; Joao P De Aquino; Benjamin L Kazer; Melissa Funaro; Marc N Potenza; Gustavo A Angarita
Journal:  Curr Addict Rep       Date:  2022-08-15

Review 2.  Ketamine plus Alcohol: What We Know and What We Can Expect about This.

Authors:  Natalia Harumi Correa Kobayashi; Sarah Viana Farias; Diandra Araújo Luz; Kissila Márvia Machado-Ferraro; Brenda Costa da Conceição; Cinthia Cristina Menezes da Silveira; Luanna Melo Pereira Fernandes; Sabrina de Carvalho Cartágenes; Vânia Maria Moraes Ferreira; Enéas Andrade Fontes-Júnior; Cristiane do Socorro Ferraz Maia
Journal:  Int J Mol Sci       Date:  2022-07-15       Impact factor: 6.208

Review 3.  Ketamine as a Novel Psychopharmacotherapy for Eating Disorders: Evidence and Future Directions.

Authors:  Anya Ragnhildstveit; Matthew Slayton; Laura Kate Jackson; Madeline Brendle; Sachin Ahuja; Willis Holle; Claire Moore; Kellie Sollars; Paul Seli; Reid Robison
Journal:  Brain Sci       Date:  2022-03-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.